Checkpoint inhibitors against the PD-1/PD-L1 pathway work by enabling anti-cancer T cells to stay active against tumors. To increase our understanding of how they work and improve their effectiveness for more patients, Dr. McGuire is investigating how PD-L1 expression on immune cells, such as macrophages and dendritic cells, influences the immune system’s ability to eliminate tumors. By looking at multiple tumor models, she determined that these PD-L1-expressing cells only affect certain T cell abilities, and only in certain parts of the body. As Dr. McGuire continues her studies, she aims to provide new details on the PD-1/PD-L1 pathway and how various cells are involved, which should guide new approaches to improve immunotherapy.
I understand the profound impact of scientific discovery on cancer immunotherapies in the clinic, and I am grateful to the CRI for supporting my research and passion to make a difference in people's lives in their fights against cancer.
Projects and Grants
The role of the PD-1/PD-ligand pathway in anti-tumor immunity
Harvard Medical School | All Cancers | 2015 | Arlene H. Sharpe, M.D., Ph.D.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.